BPH, Lower Urinary Tract Symptoms
Conditions
Brief summary
This study will evaluate LycoComfort™ supplementation in alleviating symptoms associated with LUTS, BPH, and general prostate concerns. Inflammation, oxidative stress and androgenic activity in the prostate are proven catalysts of BPH, ultimately leading to increased prostate cell proliferation. The once-daily supplement LycoComfort™, will be under investigation for symptom relief and will be taken by participants for a duration of 12 weeks.
Detailed description
LycoComfort™ is a dietary supplement containing tomato extract and phytosterols, ingredients that have been associated with relief of symptoms associated with general prostate discomfort and Lower Urinary Tract Symptoms (LUTS). The purpose of this study is to evaluate changes in these symptoms after taking this supplement daily for 12 weeks. Although it was not until the latter part of the twenties century that investigators began to explore the importance of lycopene, the benefits of this natural carotenoid are well studied. A number of clinical trials have shown lycopene to be effectual for alleviating prostate discomfort, symptoms of BPH and LUTS. The American Urological Association estimates that 90% of men between 45 and 80 years of age suffer some symptoms of LUTS. Several pathophysiological mechanisms are believed to lead to LUTS and BPH, including oxidative damage, inflammation and sympathetic nervous system issues. High blood lycopene concentrations have been suggested in epidemiological trials to be associated with decreases in oxidative stress and contributions to disease prevention overall. Also, clinical trials have shown that higher levels of lycopene in the blood are associated with a reduced risk of prostate cancer, as well as other inflammatory conditions.
Interventions
DIETARY_SUPPLEMENTLycocomfort
Evaluate of the perceived efficacy of LycoComfort™ supplements in alleviating symptoms associated with lower urinary tract symptoms (LUTS) and general prostate discomfort over the duration of 12 weeks intervention
Sponsors
LycoRed Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Males, age 40 and older * A score of 8 or greater on a self-administered I-PSS test
Exclusion criteria
* Acute or chronic prostatitis * Acute urinary retention * Allergy or sensitivity to any of the test product components (tomato \[lycopene\] or beta-sitosterol) * Cancer of the prostate (PCa) or other cancers, current or a history of PCa * Chronic diseases of the kidneys and/or liver * Hematuria of unknown etiology * Infection or malfunction of the urinary tract * Inflammatory diseases of the urogenital tract * Medication, herbal supplementation or other substance use for the treatment of urinary symptoms, BPH/LUTS, or erectile dysfunction, including medications which may affect hormonal status within 30 days before screening. These may include, but are not limited to: Sildenafil/Viagra; Tadalafil/Cialis; Vardenafil/Levitra; Herbal Viagra; Alpha-Blockers; Oral Steroids, Spironolactone or Testosterone * Previous radiotherapy of prostate * Previous surgery of the prostate, bladder or urethra
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients with a change in International Prostate Symptom Score (I-PSS) | Enrollment to 12 weeks | Change from enrollment to week 12 in prostate symptoms, measured by the Prostate Symptom Score questionnaire (I-PSS) ranged 1-35 points (1-7: Mild 8-19: Moderate 20-35: Severe). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients with a significant improvement in International Prostate Symptom Score (I-PSS) | 12 weeks | The number of subjects with a clinically significant improvement in International Prostate Symptom Score (I-PSS) at week 12, defined as an improvement of at least 3 points in a 1-35 point scale. |
| Number of patients with a change in Core Lower Urinary Tract Symptom Score (CLSS) | 12 weeks | Change from enrollment to week 12 in urinary symptoms, measured by Core Lower Urinary Tract Symptom Score (CLSS), ranged 1-31 points. |
| Satisfaction from treatment evaluated by User satisfaction questionnaire | 12 weeks | Subject satisfaction with the LycoComfort™ supplement, as derived from responses to User satisfaction Questionnaire ( 5 point Likert scale, ranged 8-45 points). |
| Adverse events (AEs) | 12 weeks | Adverse events (AEs) reported during the treatment period and classified by the Investigator as to intensity, relationship to study procedures, and seriousness |
Other
| Measure | Time frame | Description |
|---|---|---|
| Number of patients with a change in Brief Sexual Function Index (BSFI) score | 12 weeks | Change from enrollment to week 12 in sexual function, measured by Brief Sexual Function Index (BSFI) score ( ranged 0-44 points) |
Countries
United States
Outcome results
None listed